drugset
drugset / Trial / NCT05155215

Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT05155215 ↗

Phase 1/2 Unknown 68 enrolled Beijing Immunochina Medical Science & Technology Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult R/R Mantle Cell Lymphoma subjects

Timeline

Start
2021-12-31
Primary completion
2022-12-31
Completion
2023-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject IM19 CAR-T cells Cell therapy 1e+08 cells —
Subject IM19 CAR-T cells Cell therapy 2e+08 cells —
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

immunoproliferative disorder mantle cell lymphoma